Skip to content

Bausch + Lomb BLCO Non-cash interest expense

Non-cash interest expense at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$1.2B+9.4%
Operating income$33.0M+140%
Net income-$71.0M+66.5%
EPS (diluted)-$0.20+66.7%

Balance sheet

See full
Cash & equivalents$279.0M+29.8%
Total debt$5.0B+4.3%
Total equity$6.4B+0.3%
Total assets$13.8B+2.6%

Cash flow

See full
Operating cash flow$32.0M+228%
CapEx$100.0M-9.1%
Free cash flow-$68.0M+49.6%

Valuation

See full
Market cap$5.3B+10.2%
Enterprise value$10.06B+6.9%
P/S0.0×

Profitability

See full
Operating margin4.4%+2.9pp
Net margin-4.2%-1.3pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-3.4%-0.9pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.

The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch + Lomb's non-cash interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch + Lomb's non-cash interest expense?
Bausch + Lomb (BLCO) reported non-cash interest expense of $3M in Q1 2026.
How has Bausch + Lomb's non-cash interest expense changed year-over-year?
Bausch + Lomb's non-cash interest expense decreased by 40.0% year-over-year, from $5M to $3M.
What is the long-term trend for Bausch + Lomb's non-cash interest expense?
Over 3 years (2022 to 2025), Bausch + Lomb's non-cash interest expense has grown at a 31.0% compound annual growth rate (CAGR), from $8M to $18M.